Processa Pharmaceuticals, Inc. (PCSA)
|Net Income (ttm)||-5.45M|
|Trading Day||March 5|
|Day's Range||9.95 - 11.15|
|52-Week Range||3.40 - 13.35|
HANOVER, MD, March 02, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional a...
Dover, Delaware--(Newsfile Corp. - February 22, 2021) - Encode Ideas, L.P. Initiates Research on Processa Pharmaceuticals, Inc. (NASDAQ: PCSA). The full research publication is available here ...
Experienced management team with colossal past exits running 3 active mid-stage clinical programs with enough funding to generate progress through multiple value-inflection points. PCS499: Ulc...
HANOVER, MD., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to ...
Processa Pharmaceuticals, a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of post-operative ileus; and PCS6422, an oral, potent, selective, and irreversible inhibi... [Read more...]
Dr. David Young
|Stock Exchange |
|Ticker Symbol |
According to 2 analysts, the average rating for PCSA stock is "Strong Buy." The 12-month stock price forecast is 13.50, which is an increase of 25.35% from the latest price.